PROTAC MAGL degrader-1
PROTAC MAGL degrader-1 is an orally active PROTAC agent that simultaneously targets monoacylglycerol lipase (MAGL) and E3 ubiquitin ligase MDM2. PROTAC MAGL degrader-1 degrades MAGL and inhibits the binding of MDM2 to p53. PROTAC MAGL degrader-1 can partially penetrate the blood-brain barrier (BBB). PROTAC MAGL degrader-1 induces glioblastoma stem cells (GSCs) apoptosis. (E3 ligase ligand: HY-128837; target protein ligand + linker: HY-173370; target protein inhibitor: HY-15249).
Product Specifications
UNSPSC
12352005
Target
MAGL; PROTACs
Related Pathways
Metabolic Enzyme/Protease; PROTAC
Field of Research
Cancer
Smiles
ClC1=CC=C([C@@]2([H])[C@@]([H])(C3=CC=C(Cl)C=C3)N(C(N4CC(N(CC(OCCOC5=CC=C(C(C6CCN(C(OC7=CC=C([N+]([O-])=O)C=C7)=O)CC6)(O)C8=CC=C(OCO9)C9=C8)C=C5)=O)CC4)=O)=O)C(C%10=CC=C(OC)C=C%10OC(C)C)=N2)C=C1
Molecular Formula
C60H58Cl2N6O14
Molecular Weight
1158.04
References & Citations
[1]Yuan Z, et al. MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell. Cell Death Discov. 2025 Mar 20;11 (1) :109.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC401888-500 1x 500 µL
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 